Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
OpenAI Restricts Astra AI Over Cyberattack Risks 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
OXFORD, United Kingdom and MARLBOROUGH, Mass., March 06, 2018 -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced that Dr. Peter Wrighton-Smith, Chief Executive Officer, is scheduled to present at the following upcoming investor conferences.
- Cowen and Company 38th Annual Health Care Conference on Tuesday, March 13, 2018 at 10:00 a.m. ET. The conference will be held at the Boston Marriott Copley Place in Boston.
- Barclays Global Healthcare Conference on Thursday, March 15, 2018 at 10:15 a.m. ET. The conference will be held at the Loews Miami Beach Hotel in Miami Beach.
A live webcast of Dr. Wrighton-Smith’s presentation on Tuesday, March 13 will be available online from the investor relations page of the Company's corporate website at www.oxfordimmunotec.com. A webcast replay will be available approximately 24 hours after the live presentation and will be archived on the website for approximately 90 days.
About Oxford Immunotec
Oxford Immunotec Global PLC is a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions. The Company's first product is the T-SPOT®.TB test, which is used to test for tuberculosis infection. The T-SPOT.TB test has been approved for sale in over 50 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China. The Company's second product line is a range of assays for tick-borne diseases, such as Lyme disease. The Company is headquartered near Oxford, U.K. and in Marlborough, Mass. Additional information can be found at www.oxfordimmunotec.com.
T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd. Immunetics is a trademark of Immunetics, Inc.
CONTACT:
For Media and Investor Inquiries:
Karen Koski
Head of Strategy and Investor Relations
Oxford Immunotec
Tel: +1 (508) 556-1377
[email protected]
